The Scintillon Institute

The Scintillon Institute, a San Diego–based nonprofit biomedical research organization, acts as a prime recipient of federal grants in metabolic biology, neuroscience, and aging research, with 62% of its recent award footprint held as prime grants and the remainder as sub-awards under larger research consortia. The institute's portfolio spans twelve federal funding agencies and carries $78.8 million in combined obligated dollars across thirty-nine awards since the late 1990s, with sustained activity in 2024–2026.

The institute's capability portfolio centers on developing genetically encoded molecular tools for tissue- and compartment-specific manipulation of cellular metabolism, particularly redox state and cofactor ratios. Representative prime grant work includes a $6.214 million Defense Health Agency Military Medical Research and Development award (November 2024 through October 2028) on genetic risk factors and immune response in post-traumatic brain injury cognitive impairment; a $1.025 million National Institute of Neurological Disorders and Stroke Extramural Research Programs award (August 2025 through July 2027) developing a next-generation NeuroHIV model integrating iPSC-derived CNS, immune, and endothelial cells to study HIV-1 blood-brain barrier dynamics and neurocognitive disease; a $501,160 National Institute on Aging Aging Research award (May 2026 through April 2028) for genetically encoded tools to modulate NAD and NADP ratios in Drosophila aging models; and a $480,205 National Cancer Institute Cancer Biology Research award (June 2026 through May 2028) expanding xenotopic tools for compartment-specific redox stress manipulation in cancer cells. The institute also holds active grants on cerebellar-striatal circuits regulating dopamine and food intake (National Institute of Diabetes and Digestive and Kidney Diseases, $2.1 million through March 2029), thermal imaging biomarkers of aging in mice (National Institute on Aging, $529,650 through August 2026), oxygen metabolism biosensors for renal cancer (National Cancer Institute, through February 2026), and mitochondrial electron transport chain bypass mechanisms (National Institute on Aging, through September 2026).

Customer concentration sits with the National Institutes of Health, which accounts for the majority of the institute's award volume. The top five NIH components—National Institute on Aging (twelve awards), National Institute of Neurological Disorders and Stroke (six awards), National Cancer Institute (three awards), National Heart Lung and Blood Institute (three awards), and National Institute of Allergy and Infectious Diseases (three awards)—represent 69% of all awards. The Defense Health Agency, a non-NIH funder, anchors the single largest dollar award in the portfolio at $6.2 million. The institute competes predominantly in full-and-open grant mechanisms; no SBA set-aside designations appear in the award history.

As a sub-recipient, the institute partners with major research universities and institutions. Sub-award work includes sub-awards from the Research Foundation for the State University of New York (endogenous barcoding in adult neurogenesis and Alzheimer's disease, multiple fund-year cycles), Columbia University (iPSC-derived neurovascular unit modeling and blood-brain barrier dynamics, R61/R33 phased award), Scripps Research Institute (S-nitrosylation-dependent pathological protein spread in frontotemporal and Lewy body dementia), University of California San Diego (human peripheral blood mononuclear cell work on epigenetic aging signatures and exRNA sorting), the Salk Institute (cerebellar motor control circuit dissection), and the University of Colorado (Wnt signaling in therapy-resistant ovarian cancer). The institute's role in consortia suggests it brings cell and organoid engineering expertise, fluorescence-based biosensing, and in vivo model validation to multi-institution research teams.

Activity remains steady—four awards in both 2022 and 2023, rising to eight in 2024, then moderating to four each in 2025 and 2026. Nine awards face ultimate completion dates within the next twenty-four months, creating recompete opportunity in aging biology, neurological disease modeling, and cancer metabolism domains. The institute's federal grant footprint spans CFDA 93 (Health and Human Services) and CFDA 12 (Defense) programs, with no federal contract or IDIQ vehicle participation in the source data.